Seelos Therapeutics, Inc. (SEEL) — Financial statements
Income statement, balance sheet, and cash flow for Seelos Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 2 | 0.00 | 0.00 | 0.00↓100.0% | 0.38 | |
| Cost of Revenue | 30↑56724.5% | 0.05 | 0.00 | 0.00↓100.0% | 23 | |
| Gross Profit | -28↓52567.9% | -0.05 | 0.00 | 0.00↑100.0% | -22 | |
| Operating Expenses | ||||||
| R&D Expenses | 30↓48.6% | 59↑25.7% | 47↑324.7% | 11↓51.3% | 23 | |
| General & Administrative Expenses | 13↑2.4% | 12↓18.1% | 15↑93.2% | 8↑2.9% | 8 | |
| Selling & Marketing Expenses | -0.06 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 13↑1.9% | 12↓18.1% | 15↑93.2% | 8↑2.9% | 8 | |
| Other Expenses | 0.00 | 0.00↓100.0% | 0.23 | 0.00↑100.0% | -0.38 | |
| Operating Expenses | 13↓82.3% | 71↑15.0% | 62↑228.7% | 19↓36.9% | 30 | |
| Total Costs & Expenses | 43↓39.8% | 71↑15.0% | 62↑228.7% | 19↓36.9% | 30 | |
| Operating Results | ||||||
| Operating Income | -40↑42.9% | -71↓15.0% | -62↓228.7% | -19↑36.9% | -30 | |
| Depreciation & Amortization | 0.06↑7.5% | 0.05↓99.9% | 62↑228.7% | 19↑45653.7% | 0.04 | |
| EBITDA | -38↑48.6% | -73 | 0.00 | 0.00↑100.0% | -29 | |
| EBIT | -38↑48.6% | -74↓14.1% | -64↓240.3% | -19↑31.8% | -28 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.12↑15.0% | 0.11↑107.2% | -1↓1147.9% | -0.12↓197.5% | 0.12 | |
| Interest Income | 0.20↑63.6% | 0.12↑7.1% | 0.11↑151.1% | 0.05↓70.2% | 0.15 | |
| Interest Expense | 0.08↑435.7% | 0.01↓99.1% | 2↑874.4% | 0.16↑465.5% | 0.03 | |
| Non-Operating Income | -3↓203.4% | 3↓6.4% | 3↑1462.4% | 0.18↑108.9% | -2 | |
| Other Income / Expenses | 3↑200.0% | -3↑40.2% | -4↓1180.4% | -0.34↑98.4% | -22 | |
| Income Before Tax | -38↑48.5% | -74↓11.3% | -66↓245.8% | -19↑62.5% | -51 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 0.50 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -38↑48.5% | -74↓11.3% | -66↓245.8% | -19↑62.7% | -51 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -38↑50.2% | -76↓12.7% | -68↓251.4% | -19↑61.9% | -50 | |
| Bottom-Line Net Income | -38↑48.5% | -74↓11.3% | -66↓245.8% | -19↑62.7% | -51 | |
| EPS (Basic) | -7.73↑64.0% | -21.48↑3.6% | -22.29↓73.1% | -12.88↑82.7% | -74.43 | |
| EPS (Diluted) | -7.73↑64.0% | -21.48↑3.6% | -22.29↓73.1% | -12.88↑82.7% | -74.43 | |
| Weighted Average Shares | 5↑38.2% | 4↑17.0% | 3↑103.0% | 1↑120.4% | 0.68 | |
| Weighted Average Diluted Shares | 5↑38.2% | 4↑17.0% | 3↑103.0% | 1↑120.4% | 0.68 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.